FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899695757> ?p ?o ?g. }

• W2899695757 endingPage "30" @default.
• W2899695757 startingPage "25" @default.
• W2899695757 abstract "Omalizumab is a humanized monoclonal antibody which binds to human immunoglobulins E (IgE), thus preventing their interactions with both high affinity and low affinity IgE receptors. Therefore, omalizumab is currently recommended for add-on biological therapy of uncontrolled allergic asthma, mainly characterized by type 2 airway eosinophilic inflammation. Because omalizumab has been the first, and for a long time the only available monoclonal antibody for add-on treatment of type 2 asthma, some long-term studies have been published which provide a clear evidence of the therapeutic effectiveness of the anti-IgE pharmacological strategy. Within this context, the present single-centre observational study refers to 15 patients with severe allergic asthma, treated with omalizumab for at least 5 years at the Respiratory Unit of Magna Græcia University Hospital located in Catanzaro, Italy. In these asthmatic subjects we observed significant increases in asthma control test (ACT) score, with respect to baseline (14.60 ± 2.97), after 1 year (19.20 ± 2.98; p < 0.0001) and 5 years (21.67 ± 2.38; p < 0.0001) of add-on treatment with omalizumab. More importantly, omalizumab significantly lowered the number of annual asthma exacerbations (baseline: 3.66 ± 2.01) after 1 year (0.83 ± 1.14; p < 0.0001) and 5 years (0.63 ± 0.99; p < 0.0001), respectively. This excellent therapeutic outcome made it possible to drastically decrease the daily oral intake of prednisone (baseline: 22.50 ± 5.17 mg) after 1 year (1.83 ± 4.06 mg; p < 0.0001), as well as after 5 years (1.66 ± 3.61 mg; p < 0.0001). With regard to lung function, omalizumab significantly and persistently enhanced FEV1 (baseline: 1636 ± 628.4 mL) after 1 year (2000 ± 679.7 mL; p < 0.05) and 5 years (1929 ± 564.8 mL; p < 0.05), respectively. Such relevant clinical and functional improvements were associated with reductions of blood eosinophil counts (baseline: 646.0 ± 458.9 cells/μl), already detectable after 1 year (512.7 ± 327.8 cells/μl; not significant), which reached the threshold of statistical significance after 5 years (326.0 ± 171.8 cells/μl; p < 0.05). Therefore, these real-life data referring to our single-centre observational investigation further corroborate the long-term therapeutic ability of omalizumab to improve several clinical, functional and haematological signatures of severe type 2 asthma." @default.
• W2899695757 created "2018-11-16" @default.
• W2899695757 creator A5008045147 @default.
• W2899695757 creator A5009395811 @default.
• W2899695757 creator A5013135039 @default.
• W2899695757 creator A5018421075 @default.
• W2899695757 creator A5023315120 @default.
• W2899695757 creator A5028306950 @default.
• W2899695757 creator A5028562273 @default.
• W2899695757 creator A5061103978 @default.
• W2899695757 creator A5071152137 @default.
• W2899695757 date "2019-02-01" @default.
• W2899695757 modified "2023-10-18" @default.
• W2899695757 title "Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study" @default.
• W2899695757 cites W1867955398 @default.
• W2899695757 cites W1876031798 @default.
• W2899695757 cites W1982141273 @default.
• W2899695757 cites W1990584029 @default.
• W2899695757 cites W1993997407 @default.
• W2899695757 cites W1995853267 @default.
• W2899695757 cites W2005749129 @default.
• W2899695757 cites W2009933260 @default.
• W2899695757 cites W2013105339 @default.
• W2899695757 cites W2015082452 @default.
• W2899695757 cites W2027541305 @default.
• W2899695757 cites W2029319906 @default.
• W2899695757 cites W2031029516 @default.
• W2899695757 cites W2037071616 @default.
• W2899695757 cites W2040640809 @default.
• W2899695757 cites W2042788227 @default.
• W2899695757 cites W2044332962 @default.
• W2899695757 cites W2047787274 @default.
• W2899695757 cites W2053967304 @default.
• W2899695757 cites W2060015303 @default.
• W2899695757 cites W2062888033 @default.
• W2899695757 cites W2070201691 @default.
• W2899695757 cites W2085990242 @default.
• W2899695757 cites W2098968578 @default.
• W2899695757 cites W2112649669 @default.
• W2899695757 cites W2120901603 @default.
• W2899695757 cites W2121954044 @default.
• W2899695757 cites W2123042023 @default.
• W2899695757 cites W2126411802 @default.
• W2899695757 cites W2140994897 @default.
• W2899695757 cites W2155051645 @default.
• W2899695757 cites W2160175590 @default.
• W2899695757 cites W2185031583 @default.
• W2899695757 cites W2192072888 @default.
• W2899695757 cites W2224498735 @default.
• W2899695757 cites W2397424022 @default.
• W2899695757 cites W2467880758 @default.
• W2899695757 cites W2468702571 @default.
• W2899695757 cites W2562179046 @default.
• W2899695757 cites W2601782539 @default.
• W2899695757 cites W2613362962 @default.
• W2899695757 cites W2726386605 @default.
• W2899695757 cites W2738559968 @default.
• W2899695757 cites W2750584686 @default.
• W2899695757 cites W2752655957 @default.
• W2899695757 cites W2754586014 @default.
• W2899695757 cites W2755340325 @default.
• W2899695757 cites W2765417286 @default.
• W2899695757 cites W2767543075 @default.
• W2899695757 cites W2775249353 @default.
• W2899695757 cites W2791261363 @default.
• W2899695757 cites W2792973955 @default.
• W2899695757 cites W2805031704 @default.
• W2899695757 cites W2892058094 @default.
• W2899695757 cites W2900203670 @default.
• W2899695757 cites W4211175431 @default.
• W2899695757 cites W53618205 @default.
• W2899695757 doi "https://doi.org/10.1016/j.pupt.2018.11.002" @default.
• W2899695757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30414440" @default.
• W2899695757 hasPublicationYear "2019" @default.
• W2899695757 type Work @default.
• W2899695757 sameAs 2899695757 @default.
• W2899695757 citedByCount "29" @default.
• W2899695757 countsByYear W28996957572019 @default.
• W2899695757 countsByYear W28996957572020 @default.
• W2899695757 countsByYear W28996957572021 @default.
• W2899695757 countsByYear W28996957572022 @default.
• W2899695757 countsByYear W28996957572023 @default.
• W2899695757 crossrefType "journal-article" @default.
• W2899695757 hasAuthorship W2899695757A5008045147 @default.
• W2899695757 hasAuthorship W2899695757A5009395811 @default.
• W2899695757 hasAuthorship W2899695757A5013135039 @default.
• W2899695757 hasAuthorship W2899695757A5018421075 @default.
• W2899695757 hasAuthorship W2899695757A5023315120 @default.
• W2899695757 hasAuthorship W2899695757A5028306950 @default.
• W2899695757 hasAuthorship W2899695757A5028562273 @default.
• W2899695757 hasAuthorship W2899695757A5061103978 @default.
• W2899695757 hasAuthorship W2899695757A5071152137 @default.
• W2899695757 hasConcept C126322002 @default.
• W2899695757 hasConcept C141105273 @default.
• W2899695757 hasConcept C142724271 @default.
• W2899695757 hasConcept C151730666 @default.
• W2899695757 hasConcept C159654299 @default.
• W2899695757 hasConcept C203014093 @default.

• next